Regulation of endothelial cell functions by basement membrane‐ and arachidonic acid‐derived products
暂无分享,去创建一个
[1] V. Keshamouni,et al. Human α1 type IV collagen NC1 domain exhibits distinct antiangiogenic activity mediated by α1β1 integrin. , 2020, The Journal of clinical investigation.
[2] A. Pshezhetsky,et al. Caspase-3 Activation Triggers Extracellular Cathepsin L Release and Endorepellin Proteolysis* , 2008, Journal of Biological Chemistry.
[3] E. Crivellato,et al. Mast cells and tumour angiogenesis: new insight from experimental carcinogenesis. , 2008, Cancer letters.
[4] J. Redondo,et al. PGE2 induces angiogenesis via MT1-MMP-mediated activation of the TGFbeta/Alk5 signaling pathway. , 2008, Blood.
[5] A. Pozzi,et al. PPARα Ligands as Antitumorigenic and Antiangiogenic Agents , 2008, PPAR research.
[6] N. Ferrara,et al. Role of myeloid cells in tumor angiogenesis and growth. , 2008, Trends in cell biology.
[7] Baolin Zhang,et al. An essential role for SRC-activated STAT-3 in 14,15-EET-induced VEGF expression and angiogenesis. , 2008, Blood.
[8] C. Boosani,et al. RETRACTED ARTICLE: Inhibition of Tumor Angiogenesis by Tumstatin: Insights into Signaling Mechanisms and Implications in Cancer Regression , 2008, Pharmaceutical Research.
[9] Mahavir Singh,et al. Cytochrome P450 (CYP) 2J2 gene transfection attenuates MMP‐9 via inhibition of NF‐κβ in hyperhomocysteinemia , 2008, Journal of cellular physiology.
[10] B. Hudson,et al. Mammalian collagen IV , 2008, Microscopy research and technique.
[11] J. Miner. Laminins and their roles in mammals , 2008, Microscopy research and technique.
[12] R. Iozzo,et al. Novel interactions of perlecan: Unraveling perlecan's role in angiogenesis , 2008, Microscopy research and technique.
[13] N. Smyth,et al. Nidogens—Extracellular matrix linker molecules , 2008, Microscopy research and technique.
[14] L. Coussens,et al. Polarized immune responses differentially regulate cancer development , 2008, Immunological reviews.
[15] X. Xie,et al. Celecoxib inhibits tumor growth and angiogenesis in an orthotopic implantation tumor model of human colon cancer. , 2008, Experimental oncology.
[16] D. Mukherjee. Nonsteroidal anti-inflammatory drugs and the heart: what is the danger? , 2008, Congestive heart failure.
[17] M. Koch,et al. Tumor Escape from Endogenous, Extracellular Matrix–Associated Angiogenesis Inhibitors by Up-Regulation of Multiple Proangiogenic Factors , 2008, Clinical Cancer Research.
[18] J. Folkman,et al. Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. , 2008, Blood.
[19] S. Ylä-Herttuala,et al. 15-Lipoxygenase-1 Prevents Vascular Endothelial Growth Factor A– and Placental Growth Factor–Induced Angiogenic Effects in Rabbit Skeletal Muscles via Reduction in Growth Factor mRNA Levels, NO Bioactivity, and Downregulation of VEGF Receptor 2 Expression , 2008, Circulation research.
[20] A. Pozzi,et al. Integrin α2β1 Is the Required Receptor for Endorepellin Angiostatic Activity* , 2008, Journal of Biological Chemistry.
[21] S. Donnini,et al. Prostaglandin E2 Regulates Angiogenesis via Activation of Fibroblast Growth Factor Receptor-1* , 2008, Journal of Biological Chemistry.
[22] Sui Huang,et al. PPARα agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition , 2008, Proceedings of the National Academy of Sciences.
[23] I. Fleming. Vascular cytochrome p450 enzymes: physiology and pathophysiology. , 2008, Trends in cardiovascular medicine.
[24] A. Pozzi,et al. Integrin alpha2beta1 is the required receptor for endorepellin angiostatic activity. , 2008, The Journal of biological chemistry.
[25] D. Ganea,et al. PGE2-induced metalloproteinase-9 is essential for dendritic cell migration. , 2008, Blood.
[26] D. Noonan,et al. Inflammation, inflammatory cells and angiogenesis: decisions and indecisions , 2008, Cancer and Metastasis Reviews.
[27] R. Kalluri,et al. Type IV collagen α6 chain‐derived noncollagenous domain 1 (α6(IV)NC1) inhibits angiogenesis and tumor growth , 2007 .
[28] P Reddanna,et al. Computer aided drug design approaches to develop cyclooxygenase based novel anti-inflammatory and anti-cancer drugs. , 2007, Current pharmaceutical design.
[29] W. Glasgow,et al. 15(S)-HETE production in human retinal microvascular endothelial cells by hypoxia: Novel role for MEK1 in 15(S)-HETE induced angiogenesis. , 2007, Investigative ophthalmology & visual science.
[30] Sriram Krishnamoorthy,et al. Lipoxygenase metabolism: roles in tumor progression and survival , 2007, Cancer and Metastasis Reviews.
[31] Raghu Kalluri,et al. Structure and Function of Basement Membranes , 2007, Experimental biology and medicine.
[32] V. Holla,et al. Targeting cyclooxygenase-2 and the epidermal growth factor receptor for the prevention and treatment of intestinal cancer. , 2007, Cancer research.
[33] Hyunsook Kim,et al. Cyclooxygenase-2 promotes cell proliferation, migration and invasion in U2OS human osteosarcoma cells , 2007, Experimental & Molecular Medicine.
[34] V. Keshamouni,et al. Regulation of COX-2 mediated signaling by alpha3 type IV noncollagenous domain in tumor angiogenesis. , 2007, Blood.
[35] A. Pozzi,et al. Peroxisomal Proliferator-activated Receptor-α-dependent Inhibition of Endothelial Cell Proliferation and Tumorigenesis* , 2007, Journal of Biological Chemistry.
[36] A. Pozzi,et al. Prostaglandin E2-EP4 Receptor Promotes Endothelial Cell Migration via ERK Activation and Angiogenesis in Vivo* , 2007, Journal of Biological Chemistry.
[37] Baolin Zhang,et al. 15(S)-hydroxyeicosatetraenoic acid-induced angiogenesis requires STAT3-dependent expression of VEGF. , 2007, Cancer research.
[38] S. Narumiya,et al. Prostaglandin E Receptors* , 2007, Journal of Biological Chemistry.
[39] L. Coussens,et al. Humoral immunity, inflammation and cancer. , 2007, Current opinion in immunology.
[40] J. Falck,et al. Activation of Vascular Endothelial Growth Factor through Reactive Oxygen Species Mediates 20-Hydroxyeicosatetraenoic Acid-Induced Endothelial Cell Proliferation , 2007, Journal of Pharmacology and Experimental Therapeutics.
[41] Sui Huang,et al. PPARα Deficiency in Inflammatory Cells Suppresses Tumor Growth , 2007, PloS one.
[42] D. Aronoff,et al. Prostaglandin E(2) inhibits collagen expression and proliferation in patient-derived normal lung fibroblasts via E prostanoid 2 receptor and cAMP signaling. , 2007, American journal of physiology. Lung cellular and molecular physiology.
[43] Raymond N DuBois,et al. NSAIDs and cancer prevention: targets downstream of COX-2. , 2007, Annual review of medicine.
[44] I. Fleming. Epoxyeicosatrienoic acids, cell signaling and angiogenesis. , 2007, Prostaglandins & other lipid mediators.
[45] Huanchen Sha,et al. Optimizing drug delivery for enhancing therapeutic efficacy of recombinant human endostatin in cancer treatment. , 2007, Critical reviews in therapeutic drug carrier systems.
[46] Sui Huang,et al. PPAR\(\alpha\) Deficiency in Inflammatory Cells Suppresses Tumor Growth , 2007 .
[47] S. Baker,et al. The PTEN/Akt pathway dictates the direct alphaVbeta3-dependent growth-inhibitory action of an active fragment of tumstatin in glioma cells in vitro and in vivo. , 2006, Cancer research.
[48] D. Nebert,et al. The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis , 2006, Nature Reviews Cancer.
[49] A. Griffioen,et al. Monocyte/macrophage infiltration in tumors: modulators of angiogenesis , 2006, Journal of leukocyte biology.
[50] K. Camphausen,et al. Endorepellin in vivo: targeting the tumor vasculature and retarding cancer growth and metabolism. , 2006, Journal of the National Cancer Institute.
[51] A. Pozzi,et al. EP2, a receptor for PGE2, regulates tumor angiogenesis through direct effects on endothelial cell motility and survival , 2006, Oncogene.
[52] Y. Shiratori,et al. Tumor‐specific expression of the RGD‐α3(IV)NC1 domain suppresses endothelial tube formation and tumor growth in mice , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[53] I. Fleming,et al. From endothelium-derived hyperpolarizing factor (EDHF) to angiogenesis: Epoxyeicosatrienoic acids (EETs) and cell signaling. , 2006, Pharmacology & therapeutics.
[54] A. Pozzi,et al. Integrin α3β1, a Novel Receptor for α3(IV) Noncollagenous Domain and a Trans-dominant Inhibitor for Integrin αvβ3* , 2006, Journal of Biological Chemistry.
[55] D. Nie,et al. Mechanisms Regulating Tumor Angiogenesis by 12-Lipoxygenase in Prostate Cancer Cells* , 2006, Journal of Biological Chemistry.
[56] R. Kalluri,et al. Cathepsin S Controls Angiogenesis and Tumor Growth via Matrix-derived Angiogenic Factors* , 2006, Journal of Biological Chemistry.
[57] G. Alghisi,et al. Vascular integrins in tumor angiogenesis: mediators and therapeutic targets. , 2006, Endothelium : journal of endothelial cell research.
[58] A. Dannenberg,et al. Targeting Prostaglandin E2 Receptors as an Alternative Strategy to Block Cyclooxygenase-2-dependent Extracellular Matrix-induced Matrix Metalloproteinase-9 Expression by Macrophages* , 2006, Journal of Biological Chemistry.
[59] Baolin Zhang,et al. Fibroblast Growth Factor-2 Is a Downstream Mediator of Phosphatidylinositol 3-Kinase-Akt Signaling in 14,15-Epoxyeicosatrienoic Acid-induced Angiogenesis* , 2006, Journal of Biological Chemistry.
[60] A. Pozzi,et al. Integrin alpha3beta1, a novel receptor for alpha3(IV) noncollagenous domain and a trans-dominant Inhibitor for integrin alphavbeta3. , 2006, The Journal of biological chemistry.
[61] K. Lundholm,et al. Cyclooxygenase inhibition in early onset of tumor growth and related angiogenesis evaluated in EP1 and EP3 knockout tumor-bearing mice , 2006, Angiogenesis.
[62] K. Ha,et al. Prostaglandin E2 stimulates angiogenesis by activating the nitric oxide/cGMP pathway in human umbilical vein endothelial cells , 2005, Experimental & Molecular Medicine.
[63] F Peter Guengerich,et al. Function of human cytochrome P450s: characterization of the orphans. , 2005, Biochemical and biophysical research communications.
[64] R. Busse,et al. Cytochrome P450 epoxygenases 2C8 and 2C9 are implicated in hypoxia-induced endothelial cell migration and angiogenesis , 2005, Journal of Cell Science.
[65] I. Barshack,et al. Inhibition of carcinogenesis in transgenic mouse models over-expressing 15-lipoxygenase in the vascular wall under the control of murine preproendothelin-1 promoter. , 2005, Cancer letters.
[66] S. Fischer,et al. Lack of expression of the EP2 but not EP3 receptor for prostaglandin E2 results in suppression of skin tumor development. , 2005, Cancer research.
[67] Baolin Zhang,et al. 15(S)-hydroxyeicosatetraenoic acid induces angiogenesis via activation of PI3K-Akt-mTOR-S6K1 signaling. , 2005, Cancer research.
[68] A. Pozzi,et al. Characterization of 5,6- and 8,9-Epoxyeicosatrienoic Acids (5,6- and 8,9-EET) as Potent in Vivo Angiogenic Lipids* , 2005, Journal of Biological Chemistry.
[69] T. Salo,et al. Generation of biologically active endostatin fragments from human collagen XVIII by distinct matrix metalloproteases. , 2005, Experimental cell research.
[70] P. Opolon,et al. Canstatin Acts on Endothelial and Tumor Cells via Mitochondrial Damage Initiated through Interaction with αvβ3 and αvβ5 Integrins , 2005 .
[71] R. Iozzo,et al. BMP-1/Tolloid-like Metalloproteases Process Endorepellin, the Angiostatic C-terminal Fragment of Perlecan* , 2005, Journal of Biological Chemistry.
[72] J. Falck,et al. Inhibitors of cytochrome P450 4A suppress angiogenic responses. , 2005, The American journal of pathology.
[73] S. Taniura,et al. The cyclooxygenase inhibitor indomethacin modulates gene expression and represses the extracellular matrix protein laminin gamma1 in human glioblastoma cells. , 2005, Experimental cell research.
[74] R. Busse,et al. Cytochrome P4502C9-Derived Epoxyeicosatrienoic Acids Induce the Expression of Cyclooxygenase-2 in Endothelial Cells , 2004, Arteriosclerosis, thrombosis, and vascular biology.
[75] V. Keshamouni,et al. Human alpha1 type IV collagen NC1 domain exhibits distinct antiangiogenic activity mediated by alpha1beta1 integrin. , 2005, The Journal of clinical investigation.
[76] P. Opolon,et al. Canstatin acts on endothelial and tumor cells via mitochondrial damage initiated through interaction with alphavbeta3 and alphavbeta5 integrins. , 2005, Cancer research.
[77] FDA warning on NSAID use. , 2005, FDA consumer.
[78] R. Breyer,et al. Generation of a conditional allele of the mouse prostaglandin EP4 receptor , 2004, Genesis.
[79] J. Morrow,et al. Colon Carcinoma Cell Growth Is Associated with Prostaglandin E2/EP4 Receptor-evoked ERK Activation* , 2004, Journal of Biological Chemistry.
[80] Samuel A. Santoro,et al. Endorepellin causes endothelial cell disassembly of actin cytoskeleton and focal adhesions through α2β1 integrin , 2004, The Journal of cell biology.
[81] C. Witton,et al. Cyclooxygenase 2 (COX2) expression is associated with poor outcome in ER‐negative, but not ER‐positive, breast cancer , 2004, Histopathology.
[82] Tianyuan Zhang,et al. The C-terminal domain of canstatin suppresses in vivo tumor growth associated with proliferation of endothelial cells. , 2004, Biochemical and biophysical research communications.
[83] L. Claesson‐Welsh,et al. Laminin-1 Promotes Angiogenesis in Synergy with Fibroblast Growth Factor by Distinct Regulation of the Gene and Protein Expression Profile in Endothelial Cells* , 2004, Journal of Biological Chemistry.
[84] L. R. Howe,et al. Extracellular Matrix-induced Cyclooxygenase-2 Regulates Macrophage Proteinase Expression* , 2004, Journal of Biological Chemistry.
[85] K. Alitalo,et al. An Endostatin-derived Peptide Interacts with Integrins and Regulates Actin Cytoskeleton and Migration of Endothelial Cells* , 2004, Journal of Biological Chemistry.
[86] S. Gately,et al. Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy. , 2004, Seminars in oncology.
[87] N. Chandel,et al. The α4 laminin subunit regulates endothelial cell survival , 2004 .
[88] B. Hudson,et al. αvβ3 and αvβ5 Integrins Bind Both the Proximal RGD Site and Non-RGD Motifs within Noncollagenous (NC1) Domain of the α3 Chain of Type IV Collagen , 2004, Journal of Biological Chemistry.
[89] A. Imberty,et al. Characterization of Endostatin Binding to Heparin and Heparan Sulfate by Surface Plasmon Resonance and Molecular Modeling , 2004, Journal of Biological Chemistry.
[90] Xiang Fang,et al. Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function. , 2004, Progress in lipid research.
[91] J. C. Jones,et al. The alpha4 laminin subunit regulates endothelial cell survival. , 2004, Experimental cell research.
[92] B. Hudson,et al. Alpha(v)beta3 and alpha(v)beta5 integrins bind both the proximal RGD site and non-RGD motifs within noncollagenous (NC1) domain of the alpha3 chain of type IV collagen: implication for the mechanism of endothelia cell adhesion. , 2004, The Journal of biological chemistry.
[93] S. Gately. The Contributions of Cyclooxygenase-2 to Tumor Angiogenesis , 2004, Cancer and Metastasis Reviews.
[94] Tianyuan Zhang,et al. Canstatin-N fragment inhibits in vitro endothelial cell proliferation and suppresses in vivo tumor growth. , 2003, Biochemical and biophysical research communications.
[95] J. Regan. EP2 and EP4 prostanoid receptor signaling. , 2003, Life sciences.
[96] S. Adler,et al. Role of 12-lipoxygenase in the stimulation of p38 mitogen-activated protein kinase and collagen alpha5(IV) in experimental diabetic nephropathy and in glucose-stimulated podocytes. , 2003, Journal of the American Society of Nephrology : JASN.
[97] S. Donnini,et al. Angiosuppressive and angiostimulatory effects exerted by synthetic partial sequences of endostatin. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[98] N. Kalia,et al. Effects of aspirin and indomethacin on endothelial cell proliferation in vitro , 2003, Journal of gastroenterology and hepatology.
[99] R. Mansel,et al. Levels of expression of lipoxygenases and cyclooxygenase-2 in human breast cancer. , 2003, Prostaglandins, leukotrienes, and essential fatty acids.
[100] T. Veenstra,et al. Anti-angiogenic activity of human endostatin is HIF-1-independent in vitro and sensitive to timing of treatment in a human saphenous vein assay. , 2003, Molecular cancer therapeutics.
[101] H. Reber,et al. PGE(2) is generated by specific COX-2 activity and increases VEGF production in COX-2-expressing human pancreatic cancer cells. , 2003, Biochemical and biophysical research communications.
[102] K. Tryggvason,et al. Alport's syndrome, Goodpasture's syndrome, and type IV collagen. , 2003, The New England journal of medicine.
[103] R. Hynes,et al. Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrin. , 2003, Cancer cell.
[104] Raghu Kalluri,et al. Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by αvβ3 and α5β1 integrins , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[105] J. Regan,et al. Prostaglandin E2 Induced Functional Expression of Early Growth Response Factor-1 by EP4, but Not EP2, Prostanoid Receptors via the Phosphatidylinositol 3-Kinase and Extracellular Signal-regulated Kinases* , 2003, The Journal of Biological Chemistry.
[106] R. Busse,et al. Cytochrome P450 2C9‐derived epoxyeicosatrienoic acids induce angiogenesis via cross‐talk with the epidermal growth factor receptor , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[107] P. Opolon,et al. Fenofibrate inhibits angiogenesis in vitro and in vivo , 2003, Cellular and Molecular Life Sciences CMLS.
[108] Raymond N DuBois,et al. Cyclooxygenase-1 is overexpressed and promotes angiogenic growth factor production in ovarian cancer. , 2003, Cancer research.
[109] M. Cross,et al. Angiostatin and endostatin inhibit endothelial cell migration in response to FGF and VEGF without interfering with specific intracellular signal transduction pathways , 2003, FEBS letters.
[110] Shawn M. Sweeney,et al. Endorepellin, a Novel Inhibitor of Angiogenesis Derived from the C Terminus of Perlecan* , 2003, The Journal of Biological Chemistry.
[111] Yukihiko Sugimoto,et al. Host Prostaglandin E2-EP3 Signaling Regulates Tumor-Associated Angiogenesis and Tumor Growth , 2003, The Journal of experimental medicine.
[112] Ko-Hua Chen,et al. Transforming growth factor-ß2 inhibition of corneal endothelial proliferation mediated by prostaglandin , 2003, Current eye research.
[113] R. Hynes,et al. Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrin. , 2003, Cancer cell.
[114] R. Kalluri,et al. Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by alpha v beta 3 and alpha 5 beta 1 integrins. , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[115] H. Reber,et al. PGE(2) is generated by specific COX-2 activity and increases VEGF production in COX-2-expressing human pancreatic cancer cells. , 2003, Biochemical and biophysical research communications.
[116] R. Busse,et al. Epoxygenase-driven angiogenesis in human lung microvascular endothelial cells. , 2003, American journal of physiology. Heart and circulatory physiology.
[117] Yukihiko Sugimoto,et al. Host Prostaglandin E 2-EP 3 Signaling Regulates Tumor-Associated Angiogenesis and Tumor Growth , 2003 .
[118] R. Timpl,et al. Role of heparan sulfate domain organization in endostatin inhibition of endothelial cell function , 2002, The EMBO journal.
[119] K. Alitalo,et al. Endostatin associates with integrin alpha5beta1 and caveolin-1, and activates Src via a tyrosyl phosphatase-dependent pathway in human endothelial cells. , 2002, Cancer research.
[120] J. Wallace,et al. Divergent effects of new cyclooxygenase inhibitors on gastric ulcer healing: Shifting the angiogenic balance , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[121] T. Adrian,et al. Lipoxygenase inhibitors attenuate growth of human pancreatic cancer xenografts and induce apoptosis through the mitochondrial pathway. , 2002, Molecular cancer therapeutics.
[122] J. Falck,et al. Biochemical and molecular properties of the cytochrome P450 arachidonic acid monooxygenases. , 2002, Prostaglandins & other lipid mediators.
[123] E. Fleck,et al. PPAR activators inhibit endothelial cell migration by targeting Akt. , 2002, Biochemical and biophysical research communications.
[124] Young-Guen Kwon,et al. Endostatin binds to the catalytic domain of matrix metalloproteinase‐2 , 2002, FEBS letters.
[125] R. Timpl,et al. Expression and distribution of laminin alpha1 and alpha2 chains in embryonic and adult mouse tissues: an immunochemical approach. , 2002, Experimental cell research.
[126] D. Nie,et al. Cyclooxygenase, lipoxygenase and tumor angiogenesis , 2002, Cellular and Molecular Life Sciences CMLS.
[127] Jian-Kang Chen,et al. Heparin-binding EGF-like growth factor mediates the biological effects of P450 arachidonate epoxygenase metabolites in epithelial cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[128] H. Kleinman,et al. Laminin γ1 chain peptide, C-16 (KAFDITYVRLKF), promotes migration, MMP-9 secretion, and pulmonary metastasis of B16–F10 mouse melanoma cells , 2002, British Journal of Cancer.
[129] J. Engel,et al. Domain structure and organisation in extracellular matrix proteins. , 2002, Matrix biology : journal of the International Society for Matrix Biology.
[130] C. Kahn,et al. Tumstatin, an Endothelial Cell-Specific Inhibitor of Protein Synthesis , 2002, Science.
[131] Rajnish A. Gupta,et al. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2 , 2001, Nature Reviews Cancer.
[132] S. Jain,et al. Matrilysin cleavage of corneal collagen type XVIII NC1 domain and generation of a 28-kDa fragment. , 2001, Investigative ophthalmology & visual science.
[133] R. Kalluri,et al. Extracellular Matrix-derived Peptide Binds to αvβ3 Integrin and Inhibits Angiogenesis* , 2001, The Journal of Biological Chemistry.
[134] R. Iozzo,et al. Heparan sulfate proteoglycans: intricate molecules with intriguing functions. , 2001, The Journal of clinical investigation.
[135] H. Kleinman,et al. An angiogenic laminin site and its antagonist bind through the αvβ3 and α5β1 integrins , 2001 .
[136] G. Lip,et al. Plasma vascular endothelial growth factor and its receptor Flt-1 in patients with hyperlipidemia and atherosclerosis and the effects of fluvastatin or fenofibrate. , 2001, The American journal of cardiology.
[137] R. Kalluri,et al. Identification of the Anti-angiogenic Site within Vascular Basement Membrane-derived Tumstatin* , 2001, The Journal of Biological Chemistry.
[138] D. Mukhopadhyay,et al. Cell surface glypicans are low-affinity endostatin receptors. , 2001, Molecular cell.
[139] T. Veikkola,et al. Interaction of endostatin with integrins implicated in angiogenesis. , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[140] R. Busse,et al. Endothelium-Derived Hyperpolarizing Factor Synthase (Cytochrome P450 2C9) Is a Functionally Significant Source of Reactive Oxygen Species in Coronary Arteries , 2001, Circulation research.
[141] R. Kalluri,et al. Extracellular matrix-derived peptide binds to alpha(v)beta(3) integrin and inhibits angiogenesis. , 2001, The Journal of biological chemistry.
[142] H. Kleinman,et al. An angiogenic laminin site and its antagonist bind through the alpha(v)beta3 and alpha5beta1 integrins. , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[143] R. Breyer,et al. Prostanoid receptors: subtypes and signaling. , 2001, Annual review of pharmacology and toxicology.
[144] U. Felbor,et al. Generation and degradation of human endostatin proteins by various proteinases , 2000, FEBS letters.
[145] K. W. Kim,et al. Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase. , 2000, Cancer research.
[146] T. Sasaki,et al. Endostatins derived from collagens XV and XVIII differ in structural and binding properties, tissue distribution and anti-angiogenic activity. , 2000, Journal of molecular biology.
[147] R. Kalluri,et al. Two RGD-independent αvβ3 Integrin Binding Sites on Tumstatin Regulate Distinct Anti-tumor Properties* , 2000, The Journal of Biological Chemistry.
[148] P. Yurchenco,et al. Form and function: The laminin family of heterotrimers , 2000, Developmental dynamics : an official publication of the American Association of Anatomists.
[149] J. Monboisse,et al. A peptide of the alpha 3(IV) chain of type IV collagen modulates stimulated neutrophil function via activation of cAMP-dependent protein kinase and Ser/Thr protein phosphatase. , 2000, Cellular signalling.
[150] D. Nie,et al. Eicosanoid regulation of angiogenesis: role of endothelial arachidonate 12-lipoxygenase. , 2000, Blood.
[151] D. Harder,et al. Cerebral microvascular endothelial cell tube formation: role of astrocytic epoxyeicosatrienoic acid release. , 2000, American journal of physiology. Heart and circulatory physiology.
[152] Peter C. Brooks,et al. New Functions for Non-collagenous Domains of Human Collagen Type IV , 2000, The Journal of Biological Chemistry.
[153] H. Ploegh,et al. Secreted cathepsin L generates endostatin from collagen XVIII , 2000, The EMBO journal.
[154] R. Kalluri,et al. Canstatin, a Novel Matrix-derived Inhibitor of Angiogenesis and Tumor Growth* , 2000, The Journal of Biological Chemistry.
[155] R. Kalluri,et al. Two RGD-independent alpha vbeta 3 integrin binding sites on tumstatin regulate distinct anti-tumor properties. , 2000, The Journal of biological chemistry.
[156] J. Folkman,et al. The generation of endostatin is mediated by elastase. , 1999, Cancer research.
[157] J. Monboisse,et al. Identification of CD47/integrin-associated protein and alpha(v)beta3 as two receptors for the alpha3(IV) chain of type IV collagen on tumor cells. , 1999, Cancer research.
[158] T. Wilt,et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. , 1999, The New England journal of medicine.
[159] J. Monboisse,et al. A peptide of the alpha3 chain of type IV collagen protects basement membrane against damage by PMN. , 1999, Biochemical and biophysical research communications.
[160] H. Kleinman,et al. Identification of endothelial cell binding sites on the laminin γ1 chain , 1999 .
[161] V. Sukhatme,et al. Antiangiogenic activity of restin, NC10 domain of human collagen XV: comparison to endostatin. , 1999, Biochemical and biophysical research communications.
[162] H. Kleinman,et al. Identification of laminin α1 and β1 chain peptides active for endothelial cell adhesion, tube formation, and aortic sprouting , 1999 .
[163] H. Kleinman,et al. Identification of endothelial cell binding sites on the laminin gamma 1 chain. , 1999, Circulation research.
[164] H. Kleinman,et al. Identification of laminin alpha1 and beta1 chain peptides active for endothelial cell adhesion, tube formation, and aortic sprouting. , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[165] M. Nugent,et al. Antisense targeting of perlecan blocks tumor growth and angiogenesis in vivo. , 1998, The Journal of clinical investigation.
[166] W. Graier,et al. ORIGIN AND FUNCTION OF EPOXYEICOSATRIENOIC ACIDS IN VASCULAR ENDOTHELIAL CELLS: MORE THAN JUST ENDOTHELIUM‐DERIVED HYPERPOLARIZING FACTOR? , 1998, Clinical and experimental pharmacology & physiology.
[167] R. DuBois,et al. Cyclooxygenase Regulates Angiogenesis Induced by Colon Cancer Cells , 1998, Cell.
[168] S. Narumiya,et al. Patent ductus arteriosus and neonatal death in prostaglandin receptor EP4-deficient mice. , 1998, Biochemical and biophysical research communications.
[169] William Arbuthnot Sir Lane,et al. Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth , 1997, Cell.
[170] K. Honn,et al. Involvement of the multiple tumor suppressor genes and 12-lipoxygenase in human prostate cancer. Therapeutic implications. , 1997, Advances in experimental medicine and biology.
[171] D. Hanahan,et al. Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.
[172] D. Grignon,et al. Elevated 12-lipoxygenase mRNA expression correlates with advanced stage and poor differentiation of human prostate cancer. , 1995, Urology.
[173] R. Natarajan,et al. A leukocyte type of 12-lipoxygenase is expressed in human vascular and mononuclear cells. Evidence for upregulation by angiotensin II. , 1995, Arteriosclerosis, thrombosis, and vascular biology.
[174] K. Honn,et al. 12(S)-HETE is a mitogenic factor for microvascular endothelial cells: its potential role in angiogenesis. , 1995, Biochemical and biophysical research communications.
[175] A. Yayon,et al. Perlecan, basal lamina proteoglycan, promotes basic fibroblast growth factor-receptor binding, mitogenesis, and angiogenesis , 1994, Cell.
[176] D. Cheresh,et al. Requirement of vascular integrin alpha v beta 3 for angiogenesis. , 1994, Science.
[177] R. Iozzo. Perlecan: a gem of a proteoglycan. , 1994, Matrix biology : journal of the International Society for Matrix Biology.
[178] J. Tímár,et al. The lipoxygenase metabolite, 12(S)-HETE, induces a protein kinase C-dependent cytoskeletal rearrangement and retraction of microvascular endothelial cells. , 1993, Experimental cell research.
[179] K. Honn,et al. Protein kinase C-dependent effects of 12(S)-HETE on endothelial cell vitronectin receptor and fibronectin receptor , 1993, The Journal of cell biology.
[180] M. Thun,et al. Aspirin use and reduced risk of fatal colon cancer. , 1991, The New England journal of medicine.
[181] J. Huttunen,et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. , 1987, The New England journal of medicine.
[182] W. Waddell,et al. Sulindac for polyposis of the colon , 1983, Journal of surgical oncology.